Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumors found in the gastrointestinal tract of dogs and are characterized by specific cellular markers. These tumors ...

IDRx is conducting early-stage trials of its targeted therapy for patients with a type of cancer called gastrointestinal stromal tumour, or Gist, which affects between 4,000 and 6,000 people each ...

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others ...

An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...